iRhythm Technologies, Inc.

I'll research iRhythm Technologies to build an accurate profile.

Let me verify the litigation context and Welch Allyn's identity.

Company overview
iRhythm Technologies, Inc. is a Delaware-incorporated digital healthcare company founded in September 2006 and headquartered at 699 8th Street, San Francisco, California. It is publicly traded on Nasdaq (ticker IRTC) and reported approximately 2,000 full-time employees and net revenue of $591.8 million for fiscal year 2024. The company renamed itself iRhythm Holdings, Inc. in January 2026.

Products / operations
iRhythm designs, develops, and commercializes device-based ambulatory cardiac monitoring and also functions as a remote diagnostic service provider, operating through Medicare-enrolled independent diagnostic testing facilities in San Francisco, Deerfield, Illinois, and Houston, Texas, plus a manufacturing facility in Cypress, California. Its Zio platform pairs FDA-cleared, wire-free patch biosensors that record continuous ECG for up to 14 days — the Zio XT, Zio Monitor, and Zio AT systems — with cloud-based analytics software (the ZEUS system) and review by cardiac technicians. Service lines cover long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry.

Patent-litigation posture
iRhythm appears in the database once and solely as a defendant (0 plaintiff cases, 1 defendant case), consistent with an operating company defending commercial products rather than a non-practicing entity asserting an acquired portfolio. The single tracked suit was filed in the U.S. District Court for the District of Delaware — a venue used by both operating and non-practicing plaintiffs, not an Eastern District of Texas–style NPE hub.

Notable case / context
Welch Allyn, Inc. v. iRhythm Technologies, Inc. (1:24-cv-00224) was filed February 20, 2024. Welch Allyn — an ambulatory ECG and patient-monitoring manufacturer that is a subsidiary of Hill-Rom Holdings, itself owned by Baxter International — alleges infringement of patents including U.S. 8,214,007; 8,965,492; 9,155,484; and 10,159,422 by the Zio XT, Zio AT, and next-generation Zio monitors. This is a competitor-versus-competitor dispute, not an NPE action. iRhythm filed inter partes review petitions against the asserted patents; the PTAB discretionarily denied institution in 2025. iRhythm's SEC filings also reference a July 2026 Baxter settlement agreement resolving outstanding patent litigation among the parties.